A biomarker found in the blood of patients with Huntington's disease appears to mark early stages of the disease and measure response to treatment, without confusing signs of Huntington's with those of other neurodegenerative diseases.
Yi Hu, Ph.D., of Harvard Medical School and Brigham and Women's Hospital, both in Boston, and his colleagues found the biomarker – a transcriptional modulator called H2AFY (for H2A histone family, member Y) – during a gene microarray search for messenger RNA transcripts expressed at various points in the disease process. They thought that a blood biomarker for Huntington's disease (HD) might exist, because the mutant huntingtin protein that causes the disease is expressed in nearly all tissues and “may cause detectable but clinically silent changes in gene expression and biochemistry in blood cells.”
The team found H2AFY overexpressed in the blood of HD patients relative to the controls after analyzing expression data from the genomes of 8 patients with HD and 111 control subjects, including 83 patients with other neurodegenerative diseases. The researchers found that H2AFY mRNA in blood provided high sensitivity and specificity for detecting HD in this set of patients, as well as in a second independent set (Proc. Natl. Acad. Sci. U.S.A. 2011;108:17141-6).
The investigators validated the association between elevated H2AFY mRNA levels and HD in two other independent, cross-sectional, case-control studies. In the first study, they compared H2AFY mRNA levels from 36 HD patients, 9 individuals with preclinical HD who carried the huntingtin gene mutation for HD, 50 healthy people, and 1 patient with spinocerebellar ataxia-1.
H2AFY mRNA levels were high only in the individuals with clinical or preclinical HD, which “is of critical importance for therapeutic biomarker discovery because patients with premanifest and early-stage HD are most likely to benefit from disease-modifying interventions,” the researchers said. The second case-control study of 25 HD patients and 21 age- and sex-matched control subjects demonstrated that the association between high H2AFY mRNA levels and HD remained consistent over 2-3 years.
Levels of macroH2A1 – the histone protein encoded by H2AFY – in the brains of HD patients and mouse models of HD also were elevated in comparison with those in control subjects and wild-type mice, particularly in brain areas most affected by the disease.
According to Dr. Hu and his coauthors, histone deacetylase inhibitors are a leading class of potentially disease-modifying therapeutics for HD. The researchers found that they could use macroH2A1 levels to monitor the response to treatment with the histone deacetylase inhibitor sodium phenylbutyrate (SPB) in a mouse model of HD.
To determine if a similar approach could be used with H2AFY mRNA levels in humans, the investigators analyzed frozen blood samples from HD patients participating in PHEND-HD (Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease), a randomized, double-blind, phase II study. They found that longer times of patients' receiving SPB were associated with greater decreases in H2AFY mRNA levels.
Their study was funded by grants from the National Institutes of Health, the Maximillian E. & Marion O. Hoffman Foundation, the RJG Foundation, the Huntington's Disease Society of America (HDSA) Coalition for the Cure, and the New England HDSA Center for Excellence for Huntington Disease.
Two of Dr. Yu's coauthors reported serving as a consultant or scientific collaborator with companies involved in neurodegenerative disease research, as well as being coinventors listed on patent applications for diagnostics or therapeutics relating to neurodegenerative diseases.
Adviser's Viewpoint
One of the First to Vet Prevention Trial Designs?
HD is a heritable, neurodegenerative disorder of middle age that first effects muscle coordination and, in the advanced stages of the disease, cognitive ability. The HD causal mutation occurs in a gene called huntingtin (which encodes a protein product of the same name) and consists of an expanded trinucleotide repeat that results in the inclusion of a longer-than-normal polyglutamine tract in the mature protein. This leads to the development of multiple cellular changes that eventually lead to the death of a collection of susceptible neurons in the brain. Despite the identification of the causal genetic locus almost 2 decades ago, there is still no cure or disease-slowing treatment available to the HD patient.
The combination of HD's neurodegenerative nature, the standardized testing available for the causal mutation, and the high penetrance of the huntingtin mutation makes HD an excellent candidate for therapeutic prevention and disease-slowing trials.
Design of such clinical trials is underway as the neurodegenerative disease field explores ways to preemptively protect each disease's targeted neurons. These designs typically face complications regarding their power because of variability in disease course – and therefore therapeutic response – from individual to individual.